P/E Ratio Insights for AstraZeneca
Portfolio Pulse from Benzinga Insights
AstraZeneca Inc.'s stock has increased by 8.28% over the past month and by 5.85% over the past year. The company's P/E ratio is lower than the aggregate P/E of the Pharmaceuticals industry, which could indicate that the stock is undervalued or that shareholders do not expect the stock to perform better in the future.
August 08, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
AstraZeneca's lower P/E ratio compared to the industry average could indicate potential undervaluation or lower future performance.
AstraZeneca's P/E ratio is lower than the industry average, which could suggest that the stock is undervalued. However, it could also indicate that shareholders do not expect the stock to perform better in the future. This uncertainty makes the impact on the stock neutral in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100